Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

433 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Decitabine dosing schedules.
Kantarjian HM, Issa JP. Kantarjian HM, et al. Among authors: issa jp. Semin Hematol. 2005 Jul;42(3 Suppl 2):S17-22. doi: 10.1053/j.seminhematol.2005.05.006. Semin Hematol. 2005. PMID: 16015500 Review.
Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.
Kantarjian HM, O'Brien S, Cortes JE, Smith TL, Rios MB, Shan J, Yang Y, Giles FJ, Thomas DA, Faderl S, Garcia-Manero G, Jeha S, Wierda W, Issa JP, Kornblau SM, Keating M, Resta D, Capdeville R, Talpaz M. Kantarjian HM, et al. Among authors: issa jp. Clin Cancer Res. 2002 Jul;8(7):2167-76. Clin Cancer Res. 2002. PMID: 12114417 Clinical Trial.
Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.
Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, Klimek V, Slack J, de Castro C, Ravandi F, Helmer R 3rd, Shen L, Nimer SD, Leavitt R, Raza A, Saba H. Kantarjian H, et al. Among authors: issa jp. Cancer. 2006 Apr 15;106(8):1794-803. doi: 10.1002/cncr.21792. Cancer. 2006. PMID: 16532500 Clinical Trial.
Epigenetics in cancer: what's the future?
Boumber Y, Issa JP. Boumber Y, et al. Among authors: issa jp. Oncology (Williston Park). 2011 Mar;25(3):220-6, 228. Oncology (Williston Park). 2011. PMID: 21548464 Review.
RIL, a LIM gene on 5q31, is silenced by methylation in cancer and sensitizes cancer cells to apoptosis.
Boumber YA, Kondo Y, Chen X, Shen L, Gharibyan V, Konishi K, Estey E, Kantarjian H, Garcia-Manero G, Issa JP. Boumber YA, et al. Among authors: issa jp. Cancer Res. 2007 Mar 1;67(5):1997-2005. doi: 10.1158/0008-5472.CAN-06-3093. Cancer Res. 2007. PMID: 17332327
Chromatin remodeling is required for gene reactivation after decitabine-mediated DNA hypomethylation.
Si J, Boumber YA, Shu J, Qin T, Ahmed S, He R, Jelinek J, Issa JP. Si J, et al. Among authors: issa jp. Cancer Res. 2010 Sep 1;70(17):6968-77. doi: 10.1158/0008-5472.CAN-09-4474. Epub 2010 Aug 16. Cancer Res. 2010. PMID: 20713525 Free PMC article.
Targeting DNA methylation.
Issa JP, Kantarjian HM. Issa JP, et al. Clin Cancer Res. 2009 Jun 15;15(12):3938-46. doi: 10.1158/1078-0432.CCR-08-2783. Epub 2009 Jun 9. Clin Cancer Res. 2009. PMID: 19509174 Free PMC article.
Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines.
Qin T, Jelinek J, Si J, Shu J, Issa JP. Qin T, et al. Among authors: issa jp. Blood. 2009 Jan 15;113(3):659-67. doi: 10.1182/blood-2008-02-140038. Epub 2008 Oct 17. Blood. 2009. PMID: 18931345 Free PMC article.
Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia.
Oki Y, Jelinek J, Shen L, Kantarjian HM, Issa JP. Oki Y, et al. Among authors: issa jp. Blood. 2008 Feb 15;111(4):2382-4. doi: 10.1182/blood-2007-07-103960. Epub 2007 Nov 30. Blood. 2008. PMID: 18055864 Free PMC article. Clinical Trial.
Effect of cytarabine and decitabine in combination in human leukemic cell lines.
Qin T, Youssef EM, Jelinek J, Chen R, Yang AS, Garcia-Manero G, Issa JP. Qin T, et al. Among authors: issa jp. Clin Cancer Res. 2007 Jul 15;13(14):4225-32. doi: 10.1158/1078-0432.CCR-06-2762. Clin Cancer Res. 2007. PMID: 17634552
433 results
Jump to page